Double Hemibody Irradiation with GM-CSF Salvage Therapy for Refractory Chronic Lymphocytic Leukemia

Leporrier, M; Troussard, Xavier; Levaltier, Xavier; B, Vie

doi:10.3109/10428199409114148

Cited by 6 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the five patients who did not respond to ESHAP (UPN 3, 5, 9, 12 and 15), four died of disease progression (associated with an infection in one) at 3, 4, 12 and 16 months, and one patient (UPN 12) is alive at 40 months after 4-Gy hemibody radiotherapy followed by fludarabine (Famp) plus cyclophosphamide (CPM). 26,27 The last two patients (UPN 2 and UPN 8) were not assessable for the response because one died in aplasia of intra-alveolar hemorrhage after the second cycle of ESHAP and the other died of sepsis, at 2 months and 1 month, respectively. Four patients had severe infections: UPN 7, who experienced severe and unusual cytopenia after each cycle of ESHAP, had Listeria monocytogenes meningitis occurring after the fourth cycle of ESHAP; it was cured by antibiotics but delayed the next two cycles; HSC collection and ASCT were delayed too at 14 and 18 months from inclusion, respectively.…”

Section: Response To Eshap (Table 2)mentioning

confidence: 99%

Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

et al. 1998

View full text Add to dashboard Cite

Given the generally poor outcome of advanced B cell chronic lymphocytic leukemia, experimental approaches are warranted, especially for younger patients in whom classical treatments have failed. We therefore conducted a prospective singlecenter study, using polychemotherapy (ESHAP) to prepare patients for hematopoietic stem cell collection and autologous stem cell transplantation as consolidation therapy. Twenty patients entered the study. An adequate response to ESHAP was obtained in 13 patients, and sufficient stem cells for grafting were obtained in eight of the 12 patients who underwent the collection procedure. Six of these grafted patients are alive in complete clinical remission a median of 30 months after transplantation. It should be noted that we were only able to graft 40% of the patients enrolled in this study, either because a new remission could not be obtained or because not enough hematopoietic stem cells could be collected. This argues for stem cell collection as soon as a first remission is obtained, even if the autograft is done later in the course of the disease.

show abstract

Section: Response To Eshap (Table 2)mentioning

confidence: 99%